**High-Density Cryopreservation of Off-the-Shelf CAR Cells Facilitates On-demand Treatment Access**

YJ Chang, PhD, N Chen, PhD, C Chen, PhD, T Guo, PhD, JH Valdez, BS, S Gaidarova, MS, B Hancock, PhD, B Rezner, BS, Y Lentz, PhD, M Plavsic, PhD, R Anderson, PhD, R Clarke, PhD, B Valamehr, PhD

Fate Therapeutics, Inc, San Diego, CA

Abstract #2045

**INTRODUCTION**

IPS Cell Product Platform - Disruptive Approach Enabling Mass Production of Universal NK Cell and T-Cell Products. Multiplexed engineered, clonal master induced pluripotent stem cell (iPSC) lines are a renewable source for the routine, mass production of immune effector cells that address many shortcomings associated with current autologous and allogeneic donor-derived cell-based immunotherapies, including off-shelf availability for broad patient access and multi-dose administration.

**RESULTS**

Cryo-formation SCREENING Identifies Lead Formulation

**High-Density Cryopreserved iNK Cells Retain Robust Viability and Uniform Phenotype**

![Image](image-url)

**In-use Stability of High-Density Cryopreserved iNK Cells is Comparable to Control**

![Image](image-url)

**CONCLUSION**

We demonstrate the successful generation of HD-filt CAR-iNK cells and stable storage at -80°C and <-150°C without interfering with drug product integrity, identity, and function, with preclinical data demonstrating consistent viability, recovery, and potency between control arm and selected test configurations. HD-fill for off-the-shelf immunotherapies will further enable flexibility to clinicians and patients in the out-patient setting for the treatment of hematologic and solid tumors.